<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" version="2.0">
  <channel>
    <title>ORBi Collection: Médecine de la reproduction (Gynécologie, andrologie, obstétrique)</title>
    <link>http://hdl.handle.net/2268/116</link>
    <description />
    <textInput>
      <title>Le moteur de recherche Collection</title>
      <description>Chercher dans ce canal</description>
      <name>chercher</name>
      <link>http://orbi.ulg.ac.be/simple-search</link>
    </textInput>
    <item>
      <title>Hysteroscopic resection of abnormally invasive placenta residuals.</title>
      <link>http://hdl.handle.net/2268/150662</link>
      <description>Titre: Hysteroscopic resection of abnormally invasive placenta residuals.
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: Nisolle, Michelle; DELBECQUE, Katty; PERRIER d'HAUTERIVE, Sophie; FIRQUET, Anne; CHANTRAINE, Frédéric
&lt;br/&gt;
&lt;br/&gt;Résumé: OBJECTIVE: To present our experience in hysteroscopic removal of abnormally invasive placenta (AIP) residuals using bipolar energy. DESIGN: Case series. SETTING: University hospital. POPULATION: Sixteen patients with AIP residuals after 17 pregnancies. METHODS: Cases were identified by ultrasound, treated with hysteroscopic bipolar electrosurgery and oral contraceptives, and followed up by ultrasound or hysteroscopy. Nine subsequent pregnancies were described. MAIN OUTCOME MEASURES AND RESULTS: Complete removal of AIP residuals was achieved by hysteroscopic bipolar electrosurgery in all cases except one. No peroperative complications occurred. AIP residual recurred in one patient after a subsequent pregnancy and was successfully treated using the same procedure. CONCLUSIONS: AIP residual is a rare condition. Management by hysteroscopic resection using bipolar energy is save and feasible.</description>
      <pubDate>Mon, 17 Jun 2013 11:19:09 GMT</pubDate>
    </item>
    <item>
      <title>Hypoxia is not required for human endometrial breakdown or repair in a xenograft model of menstruation.</title>
      <link>http://hdl.handle.net/2268/150661</link>
      <description>Titre: Hypoxia is not required for human endometrial breakdown or repair in a xenograft model of menstruation.
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: Coudyzer, Pauline; Lemoine, Pascale; Jordan, Benedicte F.; Gallez, Bernard; Galant, Christine; Nisolle, Michelle; Courtoy, Pierre J.; Henriet, Patrick; Marbaix, Etienne
&lt;br/&gt;
&lt;br/&gt;Résumé: Menstrual endometrial breakdown induced by estradiol and progesterone withdrawal is regularly attributed to vasospasm of spiral arteries causing ischemia and hypoxia. We investigated whether hypoxia actually occurred in an in vivo model of menstruation. Three complementary approaches were used to look for signs of hypoxia in fragments of human functionalis xenografted to ovariectomized immunodeficient mice bearing pellets-releasing estradiol and progesterone, and then deprived of ovarian steroids. Hormone withdrawal 21 d after grafting induced menstrual breakdown and MMP expression within 4 d. Local partial oxygen pressure (pO2) was measured by electron paramagnetic resonance using implanted lithium phtalocyanine crystals. In mice with hormone maintenance until sacrifice, pO2 was low one week after grafting (14.8+/-3.4 mmHg) but increased twofold from the second week when tissue was largely revascularized. After 3 wk, pO2 was not modified by hormone withdrawal but was slightly increased on hormone reimpregnation 4 d after removal (34.7+/-6.1 mmHg) by comparison with hormone maintenance (27.1+/-8.6 mmHg). These results were confirmed using fluorescence quenching-based OxyLite measurements. In a further search for signs of hypoxia, we did not find significant HIF1-alpha immunostaining, nor pimonidazole adducts after hormone withdrawal. We conclude that hypoxia is not needed to trigger menstrual-like tissue breakdown or repair in human endometrial xenograft.-Coudyzer, P., Lemoine, P., Jordan, B. F., Gallez, B., Galant, C., Nisolle, M., Courtoy, P. J., Henriet, P., and Marbaix, E. Hypoxia is not required for human endometrial breakdown or repair in a xenograft model of menstruation.</description>
      <pubDate>Mon, 17 Jun 2013 11:18:11 GMT</pubDate>
    </item>
    <item>
      <title>Le cas clinique du mois. Hepatite herpetique au 3eme trimestre de la grossesse.</title>
      <link>http://hdl.handle.net/2268/150150</link>
      <description>Titre: Le cas clinique du mois. Hepatite herpetique au 3eme trimestre de la grossesse.
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: GINER LLORET, Caroline; Marotta, M-L; Vaneyck, A-S; THIRY, Anne; Foidart, Jean-Michel
&lt;br/&gt;
&lt;br/&gt;Résumé: Acute liver diseases of pregnancy are common and usually transient and reversible. Given the number of different possible diagnoses, performing a large biological screening and a proper iconographic documentation is key. It makes sure no etiology fatal to the mother and her fetus is missed.</description>
      <pubDate>Tue, 11 Jun 2013 07:33:47 GMT</pubDate>
    </item>
    <item>
      <title>Phenotypical and Genotypical Surveillance of Macrolide and Lincosamide Resistance in Group B Streptococcus in Belgium</title>
      <link>http://hdl.handle.net/2268/149753</link>
      <description>Titre: Phenotypical and Genotypical Surveillance of Macrolide and Lincosamide Resistance in Group B Streptococcus in Belgium
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: DESCY, Julie; Ackermans, Yannick; BOREUX, Raphaël; MEEX, Cécile; Rémont, Leslie; Rodriguez Cuns, Grisel; MELIN, Pierrette
&lt;br/&gt;
&lt;br/&gt;Résumé: Background: Constant increase of erythromycin (E) and clindamycin (C) resistance (R) has been observed worldwide among isolates of group B streptococci (GBS). In Belgium, through the 2000s, E R increased rapidly from 10% to up to 30%. Therefore phenotypical and molecular surveillance of E and C R has to be conducted.&#xD;
Methods: 275 clinical isolates (N1) were obtained from a Belgian surveillance for invasive GBS disease in newborns (59 isolates with 32 early- and 27 late-onset diseases) and adults (216 strains) during 2008 to 2011 and 53 isolates (N2) from vagino-rectal colonization in pregnant women in 2010. E and C MICs were determined by using Etest® (EUCAST interpretive criteria). Furthermore, for the E R isolates, the inducible (iMLS), constitutive (cMLS) and M phenotypes were assessed by a double disk diffusion test; the distribution of genes encoding RNA methylases and efflux pumps was investigated by PCR.&#xD;
Results: Of the N1 and N2 isolates, 92 (33.5%) and 15 (28.3%) were respectively R to E, with a higher rate among serotype V (p &lt;0.001) and serotype IV (p &lt;0.05). Among these 107 E-R isolates, 100 (93.5%) exhibited the MLS phenotype (R to E and CC): 73 were cMLS with E MIC50 &gt;256 mg/L and 27 iMLS with E MIC50/MIC90 12/&gt;256 mg/L. The M phenotype (R to E and S to C) was expressed by 7 (6.5%) of E R isolates with E MIC50/MIC90 4/12 mg/L. One colonizing strain presented a newly described resistance mechanism in GBS: the L phenotype (S to E and R to C) with a C MIC at 8 mg/L.&#xD;
For cMLS, the most common E R genotype was ermB (66%) (p &lt;0.05) followed by ermTR (29%) and ermB+ermTR (5%). All iMLS isolates harbored an ermTR gene except 3 (2 with ermB, 1 with both ermB and ermTR); and all M phenotype were positive for mefA/B gene.&#xD;
Conclusions:1) In Belgium, by year 2010, prevalence of macrolides R in GBS exceeded 30%, 2) MLS R phenotypes (target-site modification) were the majority mechanism; M phenotype (efflux R mechanism) was also prevalent. 3) E and C susceptibility testing and surveillance are mandatory to guide prophylaxis and treatment of serious GBS infections in penicillin-allergic patients (at high risk for anaphylaxis) but also to identify emergence of newly acquired resistance mechanisms such as the L phenotype.</description>
      <pubDate>Tue, 04 Jun 2013 03:00:07 GMT</pubDate>
    </item>
    <item>
      <title>Histology of the vaginal wall in women with pelvic organ prolapse: a literature review.</title>
      <link>http://hdl.handle.net/2268/149352</link>
      <description>Titre: Histology of the vaginal wall in women with pelvic organ prolapse: a literature review.
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: DE LANDSHEERE, Laurent; Munaut, Carine; Richelle, Betty; Maillard, Catherine; Rubod, Chrystele; Nisolle, Michelle; Cosson, Michel; Foidart, Jean-Michel
&lt;br/&gt;
&lt;br/&gt;Résumé: INTRODUCTION AND HYPOTHESIS: The pathophysiology of pelvic organ prolapse (POP) is incompletely understood. The purpose of this study is to describe the current knowledge about histology of the vaginal wall and its possible involvement in the pathogenesis of pelvic organ prolapse. METHODS: Eligible studies were selected through a MEDLINE search covering January 1986 to December 2012. The research was limited to English-language publications. RESULTS: Investigations of changes in the vaginal tissue that occur in women with genital prolapse are currently still limited and produced contrary results. The heterogeneity of the patients and the control groups in terms of age, parity and hormonal status, of the localization of biopsies and the histological methods as well as the lack of validation of the quantification procedures do not allow clear and definitive conclusions to be drawn. CONCLUSIONS: This review shows that current knowledge of the histological changes observed in women with POP are inconclusive and relatively limited. More studies are needed in this specific field to better understand the mechanisms that lead to POP.</description>
      <pubDate>Mon, 27 May 2013 20:26:47 GMT</pubDate>
    </item>
    <item>
      <title>Elévation faible d’hCG en dehors d’un contexte gravidique : à propos de deux cas et revue de la littérature</title>
      <link>http://hdl.handle.net/2268/148088</link>
      <description>Titre: Elévation faible d’hCG en dehors d’un contexte gravidique : à propos de deux cas et revue de la littérature
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: DE BACKER, Benjamin; GOFFIN, Frédéric; NISOLLE, Michelle; Minon, Jean-Marc
&lt;br/&gt;
&lt;br/&gt;Résumé: La découverte fortuite ou la persistance d’une positivité faible de l’hCG est une situation qui n’est pas inhabituelle et qui nécessite une démarche clinico-biologique pour éviter de mauvaises interprétations susceptibles de conduire à des attitudes diagnostiques ou thérapeutiques inappropriées. Lorsque toute forme de grossesse est écartée, une persistance d’hCG évoque chez beaucoup la présence d’un contexte tumoral. Cependant, la positivité des tests peut également être due à diverses causes bénignes.&#xD;
Deux cas sont décrits. Une première patiente a présenté des concentrations d’hCG faibles pendant plusieurs années, consécutivement à une fausse-couche. Après investigation, l’hypothèse retenue est celle d’une maladie trophoblastique gestationnelle quiescente. Chez une seconde patiente atteinte d’insuffisance rénale terminale, la positivité de l’hCG a été révélée préalablement à la réalisation d’un examen radiologique. Dans ce cas, l’origine serait l’accumulation d’hCG hypophysaire secondaire à la pathologie rénale.&#xD;
Ces cas illustrent l’importance d’une bonne compréhension des différentes causes d’élévation de l’hCG, qui sont revues dans cet article.; Unexpected finding or persistence of low human chorionic gonadotropin (hCG) levels is not a rare situation. It requires a clinico-biological approach in order to avoid misunderstandings that could lead to inappropriate diagnostic or therapeutic attitudes. Outside the context of a pregnancy, persistent low levels of hCG may be associated with various benign and malignant conditions, i.e. quiescent gestational trophoblastic disease (QTD), raised pituitary hCG or false positive elevation caused by circulating heterophile antibodies.&#xD;
We report the cases of two non-pregnant patients with low serum hCG. In the first case, hCG levels raised during several years following a spontaneous abortion. The likelihood of heterophilic antibodies interference was ruled out and extensive clinical investigation excluded the presence of a tumour. The diagnosis was QTD. In the second case, elevated hCG came to light as an incidental finding in a women with chronic renal failure and led the clinicians to question the laboratory. The cause was probably an increase in pituitary hCG consecutive to terminal renal failure.&#xD;
These cases illustrate the importance of understanding the biology of the hCG and the causes of its persistent low elevation, which are reviewed in this article. It is essential to demonstrate clinically the presence of a tumour in order to avoid unnecessary and ineffective chemotherapy and/or hysterectomy.</description>
      <pubDate>Wed, 08 May 2013 14:32:07 GMT</pubDate>
    </item>
    <item>
      <title>NEONATAL INVASIVE GROUP B STREPTOCOCCAL (GBS) INFECTIONS IN EUROPE</title>
      <link>http://hdl.handle.net/2268/147917</link>
      <description>Titre: NEONATAL INVASIVE GROUP B STREPTOCOCCAL (GBS) INFECTIONS IN EUROPE
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: MELIN, Pierrette; Berner, Reinhard; Afshar, Baharak; Baldassarri, Lucilla; Detcheva, Antoaneta; de la Rosa, Manuel; Kunze, Mirjam; Kriz, Paula; Efstratiou, Androulla; Hufnagel, Markus; Kilian, Mogens; SEIDEL, Laurence; Telford, John
&lt;br/&gt;
&lt;br/&gt;Résumé: Objectives: To describe clinical characteristics and capsular type of GBS isolates responsible of invasive infections in infants from Belgium, Bulgaria, Czech-Republic, Denmark, Germany, Italy, Spain and United Kingdom, representing one of the main objectives of the DEVANI (DEsign of a Vaccine Against Neonatal Infections) project.&#xD;
Methods:   Surveillance of invasive GBS infections in infants was performed from mid-2008 through December 2010. For each case, a standardized case report form was filled. Samples from cases were processed using local procedures. GBS isolates were characterised in national central labs using standardised type-specific (Ia, Ib-IX) latex agglutination and molecular typing methods.&#xD;
Results:   Data on 188 infants with invasive infection  were analysed: 144 (60.6%) early onset diseases (EOD) and 74 (39.4%) late onset diseases (LOD).  In EOD, mean/median ages at onset were 14/0 hours and the male:female ratio was 1.25.  The predominant manifestation at onset was respiratory distress (42% cases); 83% cases were associated with sepsis/bacteremia, 15% with pneumonia and 6% with meningitis.  Late-prenatal screening cultures were obtained  from 51% of cases’ mothers and only half of these were positive for GBS.  Non-elective C-section, intrapartum fever and rupture of membrane (&gt;18h) were more frequent in EO-cases’ mothers versus healthy babies’ GBS-positive mothers.  The major serotypes were III (43%), V (21%) and Ia (18%).  In LOD, mean/median ages at onset were 42/34 days and the male:female ratio was 0.9.  The predominant characteristic at onset was fever (62% cases); 70% cases were associated with sepsis and 30% with meningitis.  Very rare manifestations were osteomyelitis and cellulitis.  Serotype III was highly predominant (80.6%) followed mainly by Ia (12.5%).  Death rates were 4.7/1.5% in EOD/LOD.                                                                                                                                Conclusions:   Clinical presentations were associated with age at onset of infection.  Serotype III predominated in neonatal infections. Prenatal screening was not universal neither sensitive. Study funded through the European Commission Seventh Framework.</description>
      <pubDate>Mon, 06 May 2013 06:46:03 GMT</pubDate>
    </item>
    <item>
      <title>Group B streptococci, a European perspective with results of the DEVANI project</title>
      <link>http://hdl.handle.net/2268/147904</link>
      <description>Titre: Group B streptococci, a European perspective with results of the DEVANI project
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: MELIN, Pierrette
&lt;br/&gt;
&lt;br/&gt;Résumé: In 2011, neonatal group B streptococcal (GBS) diseases remain a global public health concern. Where consensus guidelines to detect and treat intrapartum women with GBS colonization have been widely adopted, incidence of neonatal early onset disease (EOD) has dramatically declined, however despite preventive strategies cases still occur.  The strategy was not expected to prevent all cases and there are challenges and limitations to this preventive approach.  The best strategy for European countries is still a matter of debate and intrapartum antimicrobial prophylaxis (IAP) is not widely recommended.  To adopt the best preventive strategy, we first need better data assessing more accurately the true burden of GBS diseases in the different countries. Furthermore, as the current screening-based strategy for prevention is highly effective but imperfect, given the challenges, limitations and potential complications of maternal IAP, a new approach is still needed.  &#xD;
Maternal immunization against GBS is an attractive alternative for the prevention of not only neonatal diseases but also stillbirths and maternal diseases. Vaccines against GBS may likely become the most effective and sustainable long-term preventive strategy.  But the development of vaccines with global relevance has been hampered by changes in the distribution of GBS serotypes of strains causing diseases over time and in different parts of the world.  A multivalent vaccine to cover against the more prevalent serotypes suitable for European populations might not be suitable for Asian or African populations. To overcome type-specificity, new developments target vaccines based on conserved surface antigenic proteins, such as Sip protein located at the cell surface of all GBS and on immunogenic proteins from GBS pili. A pilus-based GBS vaccine is appealing and could become a globally relevant reality. &#xD;
The DEVANI (DEsign of a Vaccine Against Neonatal Infections) programme funded through the European Commission Seventh Framework was launched on 1 January 2008 with the key objective being the assessment of European GBS epidemiology to facilitate the design of a new vaccine that will confer neonatal immunity through a durable maternal immune response. A major component was to undertake pan European surveillance of maternal colonisation, maternal GBS antibody responses and neonatal diseases in eight European countries. Through 2009 and 2010, all Belgian laboratories sending any neonatal GBS invasive isolate to the National Reference Centre for GBS were invited to bring their contribution to this project. &#xD;
Belgium, Bulgaria, Czech Republic, Denmark, Germany, Italy, Spain and the United Kingdom established specific GBS screening studies during 2008/10. Maternal vaginal/rectal swabs and sera were taken between 34-37 weeks gestation and processed using a standardised microbiological screening protocol.  Samples from neonatal cases were processed using local procedures.  For each pregnant woman and each case of GBS neonatal disease, standardized case report forms were filled. GBS isolates were characterised using standardised serological and molecular typing methods for detection of all ten GBS capsular polysaccharide types (Ia to IX). Furthermore all the collected isolates were screened by multiplex PCR and FACS analysis to evaluate respectively gene presence and surface-exposure of pili. And clonal analysis of these isolates was performed using multi-locus sequence typing (MLST). &#xD;
The main microbiological results of this pan European surveillance are following.  Carriage rates among pregnant women in all countries ranged from 8% to 26%. The most common GBS capsular types were III (33%), Ia (25%) and V (8%). Among GBS from EOD, the major serotypes were III (43%), V (21%) and Ia (18%).  In contrast among GBS isolated from neonatal late onset disease (LOD), serotype III was highly predominant (80.6%) followed mainly by Ia (12.5%).&#xD;
Analysis of the pattern of pili genes showed that all isolates contained at least one gene coding for pili. The most common gene patterns found were PI-2a alone, PI 1+2a and PI 1+2b, while the PI-2b gene alone was very rare. The most prominent result was that a majority of isolates from neonatal infections carried the PI-1+2b gene pattern, while the most common pattern among pregnant women was PI-1+2a. Most of analyzed strains express at least one pilus on their surface.&#xD;
The clonal analysis showed that 66 sequence types were found to belong to nine clonal complexes (CC). Among these nine CCs, five were prevailing and covered 92 % of GBS isolates tested. The GBS population in pregnant women was found to be more heterogeneous than the GBS isolated from neonatal infection cases. Among neonatal isolates, the most frequent CC was CC17 (43 %) known as a highly virulent clone. Among participating countries, there were no significant differences in the occurrence of clonal complexes.&#xD;
The analysis of the levels of specific antibodies as surrogate markers of protection is still ongoing. &#xD;
More detailed and additional results as the main conclusions will be presented.</description>
      <pubDate>Sat, 04 May 2013 13:47:53 GMT</pubDate>
    </item>
    <item>
      <title>GBS colonization and screening in pregnancy: how does it work in Europe?</title>
      <link>http://hdl.handle.net/2268/147903</link>
      <description>Titre: GBS colonization and screening in pregnancy: how does it work in Europe?
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: MELIN, Pierrette
&lt;br/&gt;
&lt;br/&gt;Résumé: In Europe, as in North America, GBS infections among infants are associated to high morbidity and mortality even if some differences exist between different European countries.&#xD;
During the past two decades, major initiatives have been proposed to prevent early onset GBS disease (EOD) and they are still subject of controversy.  Several European countries have issued guidelines for the prevention of neonatal GBS diseases, either universal screening-based or risk-based strategy, others have no official guidelines at all.  In countries having guidelines, despite considerable efforts and economic resources spent on intrapartum antimicrobial prophylaxis for GBS EOD, cases continue to occur. Among these cases there are a lot of missed opportunities to administer IAP but there are also false negative screening. Therefore in the setting of a maternal GBS-screening program and successful implementation of the strategy, efforts to improve screening for GBS status remain important.&#xD;
The natural reservoir for GBS is the gastrointestinal tract and is likely the source for vaginal colonization.  Among pregnant women, GBS carriage rate in the vaginal and rectal flora ranges from 10% up to 30%.  Critical factors that influence the accuracy of detecting GBS maternal colonization are the choice of the body sites sampled, the timing of sampling and the use of selective culture media.  The evolution of the different culture options to improve the GBS-screening strategy will be reviewed. &#xD;
If the optimal time for performing antenatal cultures is between 35 to 37 weeks’ gestation, as GBS carriage is highly variable, the predictive values of GBS antenatal cultures are not always as good predictors of the maternal GBS status at presentation for delivery as expected.&#xD;
Potential alternative to antenatal GBS-screening culture is the identification of GBS colonization at presentation for delivery.  Use of a reliable, sensitive, easy to use rapid test should be cost effective leading to the prevention of more EOGBS cases while reducing the number of unnecessarily IAP.  Advances of polymerase chain reaction (PCR) and fluorescence labeling technologies has provided new detection tools for bacterial identification.  Therefore, commercialization of rapid detection of GBS through real-time PCR offers the potential for GBS detection among women without prenatal care or those in whom no antenatal culture was collected.  However questions of costs and logistics remain unanswered.&#xD;
Could such rapid intrapartum test replace existing screening strategies or could it be used in conjunction with them?&#xD;
Colonizing rates and recommended screening procedures existing through Europe will be reviewed.</description>
      <pubDate>Sat, 04 May 2013 13:35:11 GMT</pubDate>
    </item>
    <item>
      <title>GBS AND THE NEONATE: PREVENTION STRATEGIES</title>
      <link>http://hdl.handle.net/2268/147897</link>
      <description>Titre: GBS AND THE NEONATE: PREVENTION STRATEGIES
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: MELIN, Pierrette
&lt;br/&gt;
&lt;br/&gt;Résumé: Streptococcus agalactiae, or group B streptococcus (GBS), remains the leading cause of neonatal sepsis and meningitis, early onset and late onset diseases (EOD, LOD). &#xD;
Where consensus guidelines to detect and treat intrapartum women with GBS colonization have been widely adopted, incidence of neonatal EOD has dramatically declined.  In response to both successful impacts on the incidence of GBS-EOD and analyses of missed opportunities, the first American guidelines for prevention issued in the 90s have since been adapted in several stages to improve their efficacy.  In some countries in Europe, nationwide guidelines, whether screening-based or risk-based, for the prevention of neonatal GBS diseases have also been issued and adopted, with the expected impact on incidence of GBS-EOD.  In spite of universal screening, in spite of the great progress that has been made, GBS-EOD continues to occur and the GBS burden remains a significant public health issue.  Continuous efforts to improve screening for GBS status continue to be important and may be able to take advantage of new rapid diagnostic technologies.  The current screening-based strategy for prevention is highly effective but imperfect.  Given the challenges, limitations and potential complications of maternal intrapartum prophylaxis, a new approach is still needed.  &#xD;
Maternal immunization against GBS is an attractive alternative for the prevention of not only neonatal diseases but also stillbirths and maternal diseases.  Vaccines against GBS may likely become the most effective and sustainable long-term preventive strategy.</description>
      <pubDate>Sat, 04 May 2013 11:18:38 GMT</pubDate>
    </item>
    <item>
      <title>Role of Gamma Delta T cells in HPV-induced Cancer Progression</title>
      <link>http://hdl.handle.net/2268/144687</link>
      <description>Titre: Role of Gamma Delta T cells in HPV-induced Cancer Progression
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: Van hede, Dorien; Bastin, Renaud; Francis, Floriane; Bisig, Bettina; Arrese Estrada, Jorge; Renoux, Virginie; Dortu, Estelle; Langers, Inge; Delvenne, Philippe; Vermijlen, David; Jacobs, Nathalie</description>
      <pubDate>Wed, 13 Mar 2013 11:35:55 GMT</pubDate>
    </item>
    <item>
      <title>Role of γδ T cells in HPV-induced cancer progression</title>
      <link>http://hdl.handle.net/2268/144675</link>
      <description>Titre: Role of γδ T cells in HPV-induced cancer progression
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: Van hede, Dorien; Bastin, Renaud; Francis, Floriane; Bisig, Bettina; Arrese Estrada, Jorge; Renoux, Virginie; Dortu, Estelle; Langers, Inge; Delvenne, Philippe; Jacobs, Nathalie</description>
      <pubDate>Wed, 13 Mar 2013 09:59:39 GMT</pubDate>
    </item>
    <item>
      <title>Role of γδ T cells in HPV-induced cancer progression</title>
      <link>http://hdl.handle.net/2268/144671</link>
      <description>Titre: Role of γδ T cells in HPV-induced cancer progression
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: Van hede, Dorien; Bastin, Renaud; Francis, Floriane; Bisig, Bettina; Arrese Estrada, Jorge; Renoux, Virginie; Dortu, Estelle; Langers, Inge; Delvenne, Philippe; Vermijlen, David; Jacobs, Nathalie</description>
      <pubDate>Wed, 13 Mar 2013 09:35:26 GMT</pubDate>
    </item>
    <item>
      <title>γδ T cells could promote cancer progression of HPV-induced lesions</title>
      <link>http://hdl.handle.net/2268/144669</link>
      <description>Titre: γδ T cells could promote cancer progression of HPV-induced lesions
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: Van hede, Dorien; Bastin, Renaud; Francis, Floriane; Bisig, Bettina; Arrese Estrada, Jorge; Renoux, Virginie; Dortu, Estelle; Langers, Inge; Boniver, Jacques; Delvenne, Philippe; Vermijlen, David; Jacobs, Nathalie</description>
      <pubDate>Wed, 13 Mar 2013 09:20:37 GMT</pubDate>
    </item>
    <item>
      <title>CERTOLIZUMAB PEGOL DID NOT RESULT IN A DECREASE IN SEMEN QUALITY IN HEALTHY VOLUNTEERS: RESULTS FROM A PHASE 1 STUDY</title>
      <link>http://hdl.handle.net/2268/144354</link>
      <description>Titre: CERTOLIZUMAB PEGOL DID NOT RESULT IN A DECREASE IN SEMEN QUALITY IN HEALTHY VOLUNTEERS: RESULTS FROM A PHASE 1 STUDY
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: Perrier d'Hauterive, Sophie; KESSELER, Sophie; RUGGERI, Philippe; TIMMERMANS, Marie; GASPARD, Olivier; Kumke, T; Parker, G</description>
      <pubDate>Thu, 07 Mar 2013 11:21:35 GMT</pubDate>
    </item>
    <item>
      <title>Prise en charge des pathologies gynécologiques bénignes par chirurgie robotique</title>
      <link>http://hdl.handle.net/2268/143951</link>
      <description>Titre: Prise en charge des pathologies gynécologiques bénignes par chirurgie robotique
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: BRENEZ, Anne; PETIT, Philippe; DECHENNE, Valérie; Nisolle, Michelle</description>
      <pubDate>Thu, 28 Feb 2013 04:00:49 GMT</pubDate>
    </item>
    <item>
      <title>Phenotypical and genotypical surveillance of macrolide and lincosamide resistance in group B streptococcus in Belgium</title>
      <link>http://hdl.handle.net/2268/143674</link>
      <description>Titre: Phenotypical and genotypical surveillance of macrolide and lincosamide resistance in group B streptococcus in Belgium
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: DESCY, Julie; ACKERMANS, Yanick; BOREUX, Raphaël; MEEX, Cécile; Rémont, Leslie; Rodriguez Cuns, Grisel; MELIN, Pierrette
&lt;br/&gt;
&lt;br/&gt;Résumé: Background: Constant increase of erythromycin (E) and clindamycin (C) resistance (R) has been observed worldwide among isolates of group B streptococci (GBS). In Belgium, through the 2000s, E R increased rapidly from 10% to up to 30%. Therefore phenotypical and molecular surveillance of E and C R has to be conducted.&#xD;
Methods: 275 clinical isolates (N1) were obtained from a Belgian surveillance for invasive GBS disease in newborns (59 isolates with 32 early- and 27 late-onset diseases) and adults (216 strains) during 2008 to 2011 and 53 isolates (N2) from vagino-rectal colonization in pregnant women in 2010. E and C MICs were determined by using Etest® (EUCAST interpretive criteria). Furthermore, for the E R isolates, the inducible (iMLS), constitutive (cMLS) and M phenotypes were assessed by a double disk diffusion test; the distribution of genes encoding RNA methylases and efflux pumps was investigated by PCR.&#xD;
Results: Of the N1 and N2 isolates, 92 (33.5%) and 15 (28.3%) were respectively R to E, with a higher rate among serotype V (p &lt;0.001) and serotype IV (p &lt;0.05). Among these 107 E-R isolates, 100 (93.5%) exhibited the MLS phenotype (R to E and CC): 73 were cMLS with E MIC50 &gt;256 mg/L and 27 iMLS with E MIC50/MIC90 12/&gt;256 mg/L. The M phenotype (R to E and S to C) was expressed by 7 (6.5%) of E R isolates with E MIC50/MIC90 4/12 mg/L. One colonizing strain presented a newly described resistance mechanism in GBS: the L phenotype (S to E and R to C) with a C MIC at 8 mg/L. For cMLS, the most common E R genotype was ermB (66%) (p &lt;0.05) followed by ermTR (29%) and ermB+ermTR (5%). All iMLS isolates harbored an ermTR gene except 3 (2 with ermB, 1 with both ermB and ermTR); and all M phenotype were positive for mefA/B gene.&#xD;
Conclusions:1) In Belgium, by year 2010, prevalence of macrolides R in GBS exceeded 30%, 2) MLS R phenotypes (target-site modification) were the majority mechanism; M phenotype (efflux R mechanism) was also prevalent. 3) E and C susceptibility testing and surveillance are mandatory to guide prophylaxis and treatment of serious GBS infections in penicillin-allergic patients (at high risk for anaphylaxis) but also to identify emergence of newly acquired resistance mechanisms such as the L phenotype.</description>
      <pubDate>Mon, 25 Feb 2013 04:01:43 GMT</pubDate>
    </item>
    <item>
      <title>Isoform 111 of vascular endothelial growth factor (VEGF111) improves angiogenesis of ovarian tissue xenotransplantation</title>
      <link>http://hdl.handle.net/2268/143546</link>
      <description>Titre: Isoform 111 of vascular endothelial growth factor (VEGF111) improves angiogenesis of ovarian tissue xenotransplantation
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: Labied, Soraya; Delforge, Yves; Blacher, Silvia; Munaut, Carine; Signolle, Nicolas; Colige, Alain; Janssen, Lauriane; HENRY, Laurie; Perrier d'Hauterive, Sophie; JOUAN, Caroline; Kirschvink, Nathalie; Noël, Agnès; Nisolle, Michelle; Foidart, Jean-Michel</description>
      <pubDate>Thu, 21 Feb 2013 17:16:58 GMT</pubDate>
    </item>
    <item>
      <title>Does vascular endothelial growth factor improve ovarian tissue recovery after cryopreservation?</title>
      <link>http://hdl.handle.net/2268/143545</link>
      <description>Titre: Does vascular endothelial growth factor improve ovarian tissue recovery after cryopreservation?
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: Henry, Laurie; Fransolet, Maïté; Labied, Soraya; Blacher, Silvia; Munaut, Carine; Colige, Alain; Kirschvink, N; Noël, Agnès; Nisolle, Michelle; Foidart, Jean-Michel</description>
      <pubDate>Thu, 21 Feb 2013 17:16:22 GMT</pubDate>
    </item>
    <item>
      <title>Adverse obstetrical outcomes after treat- ment of precancerous cervical lesions : a Belgian multicenter study</title>
      <link>http://hdl.handle.net/2268/143457</link>
      <description>Titre: Adverse obstetrical outcomes after treat- ment of precancerous cervical lesions : a Belgian multicenter study
&lt;br/&gt;
&lt;br/&gt;Auteur, co-auteur: Simoens, C; GOFFIN, Frédéric; Simon, P; Barlow, P; Antoine, J; Foidart, Jean-Michel; Arbijn, M</description>
      <pubDate>Thu, 21 Feb 2013 10:46:09 GMT</pubDate>
    </item>
  </channel>
</rss>

